Multiple cancers, such as melanoma, colorectal cancer, prostate cancer, liver cancer, breast cancer, glioma, and ovarian cancer, benefit from therapy targetting RRM2 (5, 28, 29). This evidence concerns the gene RRM2 and Familial prostate cancer.